Pharmacogenetics of Treatment Response in Psoriatic Arthritis
Open Access
- 17 May 2015
- journal article
- review article
- Published by Springer Nature in Current Rheumatology Reports
- Vol. 17 (7) , 44-518
Abstract
TNF-blocking agents, non-biological disease-modifying anti-rheumatic drugs (nbDMARDs) and non-steroidal anti-inflammatory drugs (NSAIDs) are commonly prescribed treatments in psoriatic arthritis. A large proportion of patients do not respond to these medications, although unfortunately clinically useful biomarkers that predict future response are currently lacking. Several candidate gene polymorphisms have been associated with responses to biologic therapies and nbDMARDs; however, replication and validation of these variants in large prospective psoriatic arthritis cohorts are required before translating these to clinical practice. In this review, we discuss the advances made in pharmacogenetics of treatment response in psoriatic arthritis to date, with focus on biologic therapies approved for use, nbDMARDs and NSAIDs, as well as outline emerging methodologies to obtain data that will help inform a future precision medicine approach in this condition.Keywords
This publication has 65 references indexed in Scilit:
- The TICOPA protocol (TIght COntrol of Psoriatic Arthritis): a randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritisBMC Musculoskeletal Disorders, 2013
- Polymorphisms in cytochrome P450 2C19 enzyme and cessation of leflunomide in patients with rheumatoid arthritisArthritis Research & Therapy, 2012
- TNFAIP3 Gene Polymorphisms Are Associated with Response to TNF Blockade in PsoriasisJournal of Investigative Dermatology, 2012
- Accuracy of Various Human NAT2 SNP Genotyping Panels to Infer Rapid, Intermediate and Slow Acetylator PhenotypesPharmacogenomics, 2011
- Pharmacogenetics: past, present and futureDrug Discovery Today, 2011
- Confirmation of TNIP1 and IL23A as susceptibility loci for psoriatic arthritisAnnals of the Rheumatic Diseases, 2011
- Predicting the outcome of ankylosing spondylitis therapyAnnals of the Rheumatic Diseases, 2011
- Rheumatoid arthritis risk allele PTPRC is also associated with response to anti–tumor necrosis factor α therapyArthritis & Rheumatism, 2010
- Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics RegisterRheumatology, 2010
- Biomarkers and surrogate endpoints: Preferred definitions and conceptual frameworkClinical Pharmacology & Therapeutics, 2001